The Dana–Farber Cancer Institute is sponsoring a clinical study to investigate the MDM2 inhibitor ALRN-6924 as a monotherapy for different types of cancer, including leukemia, brain tumors, solid tumors, and lymphoma. Here, MDM2 is linked to cancer.